Urgent.News

the world's headlines, one feed

Editions

Business

Truck manufacturer: Daimler Truck is building a new US plant - and expects hundreds of millions of euros in customs reimbursement

The group's profit plummeted by 72 percent in the first half of the year. However, there is a turnaround in the important US market. The management has made contradictory statements about a new factory there.

Translated from German Read in German

Truck manufacturer: Daimler Truck is building a new US plant - and expects hundreds of millions of euros in customs reimbursement

Düsseldorf. The commercial vehicle manufacturer Daimler Truck wants to build a new plant in the USA. This is intended to reduce the burden of tariffs imposed by US President Donald Trump and improve the DAX group's position in the important North American market. A specific location has not yet been determined, but construction is scheduled to begin at the end of the year.

The plant is scheduled to start operations in 2029. The US business has a multiple impact on the balance sheet of the group based in Leinfelden-Echterdingen near Stuttgart. The profit before interest and taxes (EBIT) adjusted for special effects fell by 36 percent to 2.1 billion euros in the first half-year. The net profit even plummeted by 72 percent to 277 million euros.

This was mainly due to the weakening North America business and customs payments. In the region, the adjusted EBIT fell by 55 percent, and sales and revenue also shrank. However, the group expects a significant improvement in the second half-year. Due to the reimbursement of US tariffs and the recovery of the North American market, the management now expects an adjusted result of 3.6 to 4.1 billion euros for the year.

Previously, it was 3.2 to 3.7 billion. The group thus confirmed the information from an ad hoc announcement at the end of July.

Translated by urgent.news from Handelsblatt's report; automated translation may contain errors. Machine-written — it may contain errors, so check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at handelsblatt.com →

More in Business

Samsung Bioepis Files Korea’s First Keytruda Biosimilar Application

Domestic approval procedures have begun in earnest as companies move to gain an early foothold in the biosimilar market for Keytruda, the world’s biggest blockbuster drug with annual sales of 46…

  • Samsung Bioepis files first Keytruda biosimilar application in Korea.
  • SB27 biosimilar targets immuno-oncology treatments, developed by Merck.
  • Application covers 16 diseases, Samsung has 11 biosimilars in market.
Bain Capital set to acquire Gong Cha

Bain Capital set to acquire Gong Cha

Bain Capital a leading global private investment firm has agreed to acquire Gong cha Global one of the world s fastest growing tea brands from TA Associates and the company s other shareholders